View Author
dai: 298690071
scopus: 8073927600

Buster, E.H.C.J.

(Erik Buster)


patient hepatitis hepatitis b hbeag therapy treatment response peg-ifn genotype study lamivudine hbeag loss hbv dna level hbsag virus liver serum hbv genotype serum hbv dna hepatitis b virus infection hbv dna levels hbeag-positive hepatology baseline interferon hbeag seroconversion entecavir combination peginterferon follow-up group seroconversion hepatitis b patients month analogue disease hbsag loss peg-ifn therapy gastroenterology cirrhosis resistance nucleo analysis transmission relapse hepatol flare result adefovir university fibrosis janssen table factor hospital 32 weeks man ra schalm sw virological response fi brosis figure outcome lamivudine therapy 105 copies /ml assay response rates effect liver disease predictor interferon alfa responder ltfu study week 32 piratvisuth t hbv infection hbeag relapse van zonneveld m health care workers




10 Most Recent Publications

The importance of HBV genotype in HBeAg-positive chronic hepatitis B patients in whom sustained response is pursued (Article)
Buster, E.H.C.J. Janssen, H.L.A.
2011-01-01
Prediction of the response to peg-interferon-alfa in patients with HBeAG positive chronic hepatitis B using decline of HBV DNA during treatment (Article)
Hansen, B.E. Buster, E.H.C.J. Steyerberg, E.W. Lesaffre, E.M.E.H. Janssen, H.L.A.
2010-07-01
The importance of HBV genotype in HBeAg-positive chronic hepatitis B patients in whom sustained response is pursued (Article)
Buster, E.H.C.J. Janssen, H.L.A.
2010-01-01
Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa (Article)
Buster, E.H.C.J. Hansen, B.E. Lau, G.K.K. Piratvisuth, T. Zeuzem, S. Steyerberg, E.W. Janssen, H.L.A.
2009-12-01
Chronic Hepatitis B: Individualized Antiviral Therapy (Doctoral Thesis)
Buster, E.H.C.J.
2009-10-23
Early hbeag loss during peginterferon α-2b therapy predicts HBsAg loss: Results of a long-term follow-up study in chronic hepatitis B patients (Article)
Buster, E.H.C.J. Flink, H.J. Hansen, B.E. Janssen, H.L.A. Simsek, H. Heathcote, E.J. Sharmila, S. Kitis, G.E. Gerken, G. Buti, M. Vries, R.A. de Verhey, E.
2009-10-01
Comments on the EASL practice guidelines for the management of chronic hepatitis B: Controversies in interferon-based therapy (Article)
Janssen, H.L.A. Buster, E.H.C.J.
2009-07-01
Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues (Article)
Buster, E.H.C.J. Schalm, S.W. Janssen, H.L.A.
2008-12-01
Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b (Article)
Buster, E.H.C.J. Flink, H.J. Schutten, M. Tielemans, W. Vuuren, A.J. van Hansen, B.E. Janssen, H.L.A. Cakaloglu, Y. Simon, K. Trojan, J. Tabak, F. So, T.M.K. Feinman, S.V. Mach, T. Akarca, U.S.
2008-08-01
Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine (Article)
Buster, E.H.C.J. Vuuren, A.J. van Zondervan, P.E. Metselaar, H.J. Tilanus, H.W. Man, R.A. de
2008-01-01
  • rss icon RSS Publication Feed
  • foaf icon FOAF Profile